The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction

Journal of Sexual Medicine

Volumn 4, Issue 4 I, 2007, Pages 1046-1055

  Guay, Andre T ^a   Jacobson, Jerilynn ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Erectile dysfunction; Hypogonadism; Impotence; Insulin resistance; Metabolic syndrome

Indexed keywords

TESTOSTERONE;

ARTICLE; CARDIOVASCULAR RISK; CHI SQUARE TEST; CONTROLLED STUDY; DISEASE ASSOCIATION; ERECTILE DYSFUNCTION; HUMAN; HYPOGONADISM; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STUDENT T TEST;

EID: 34447526135     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00530.x     Document Type: Article

References (71)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
2. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, Wilson PW, REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.
3. Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002; 5: 19-24.
4. Kloner RA, Mullin SH, Shook T, Matthews R, Mayeda G, Burstein S, Peled H, Pollick C, Choudhary R, Rosen R, Padma-Nathan H. Erectile dysfunction in the cardiac patient: How common and should we treat? J Urol 2003; 170: S46-S50.
5. Pinnock CB, Stapleton AMF, Marshall VR. Erectile dysfunction in the community: A prevalence study. Med J Aust 1999; 171: 353-7.
6. Billups KL, Bank AJ, Padma-Nathan H, Katz S, Williams R. Erectile dysfunction is a marker for cardiovascular disease: Results of the Minority Health Institute Expert Advisory Panel. J Sex Med 2005; 2: 40-52.
7. Ponholzer A, Temml C, Obermayr R, Wehrberger C, Madersbacher S. Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? Eur Urol 2005; 48: 512-8.
8. Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, Galli S, Ravagnani PM, Montorsi P. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360-5.
9. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996-3002.
10. Montorsi P. Erectile dysfunction and subsequent cardiovascular disease. Eur Urol 2006; 49: 754-5.
11. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction: Role of the endothelium in erectile physiology and disease. J Androl 2003; 24: S17-37.
12. Guay AT. Relation of endothelial cell function to erectile dysfunction: Implication for treatment. Am J Cardiol 2005; 96: 52M-6.
13. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilatation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179-84.
14. Mass R, Schwedhelm E, Albsmeir J, Boger RH. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 2002; 7: 213-25.
15. Vlachopoulos C, Rokkas K, Ioakeimidis N, Aggeli C, Michaelides A, Roussakis G, Fassoulakis C, Askitis A, Stefanadis C. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: A prospective angiographic study. Eur Urol 2005; 48: 996-1003.
16. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 2005; 90: 5698-703.
17. Esposito K, Giugliano F, Martedi E, Feola G, Marfella R, D'Armiento M, Giugliano D. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005; 28: 1201-3.
18. Corona G, Mannucci E, Schulman C, Petrone L, Mansani R, Cilotti A, Balercia G, Chiarini V, Forti G, Maggi M. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 2006; 50: 595-604.
19. Kupelian V, Shabsigh R, Araujo AB, O'Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men; results from the Massachusetts Male Aging Study. J Urol 2006; 176: 222-6.
20. Jackson G. The metabolic syndrome and erectile dysfunction; multiple vascular risk factors and hypogonadism. Eur Urol 2006; 50: 426-7.
21. Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium. Am J Med 2004; 117: 109-17.
22. Suzuki M, Takamisawa I, Suzuki K, Hiuge A, Horio T, Yoshimasa Y, Harano Y. Close association of endothelial dysfunction with insulin resistance and carotid wall thickening in hypertension. Am J Hypertens 2004; 17: 228-32.
23. Carnethon MR, Palaniappan LP, Burchfiel CM, Brancati FL, Fortmann SP. Serum insulin, obesity, and the incidence of type 2 diabetes in black and white adults. Diabetes Care 2002; 25: 1358-64.
24. Couillard C, Ruel G, Archer WR, Pomerleau S, Bergeron J, Couture P, Lamarche B, Bergeron N. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J Clin Endocrinol Metab 2005; 90: 6454-9.
25. Calabro P, Chang DW, Willerswon JT, Yeh ETH. Release of C-reactive protein in response to inflammatory cytokines by human adiposities; linking obesity to vascular inflammation. J Am Coll Cardiol 2005; 46: 1112-3.
26. Shapsigh R, Katz M, Yan G, Makshida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005; 96 (suppl): 67M-72M.
27. Kupelian V, Page ST, Aruajo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in non-obese men. J Clin Endocrinol Metab 2006; 91: 843-50.
28. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome; implications for testosterone therapy. J Urol 2005; 174: 827-34.
29. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and the metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-23.
30. Tong PCY, Ho CS, Yeung VTF, Ng MC, So WY, Ozaki R, Ko GT, Ma RC, Poon E, Chan NN, Lam CW, Chan JC. Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 6418-23.
31. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906.
32. Pittleloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005; 90: 2636-41.
33. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-41.
34. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance. Diabetes Care 2004; 27: 861-8.
35. Guay AT, Velasquez E, Perez JB. Characterization of patients in a medical endocrine-based center for male sexual dysfunction. Endocr Pract 1999; 5: 314-21.
36. Bansal TC, Guay AT, Jacobson J, Woods BO, Nesto RW. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med 2005; 2: 96-103.
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III. JAMA 2001; 285: 2486-97.
38. World Health Organization. Definition diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Available at: http://whqlibdoc.who.int/hq/1999.WHO_NCD_NCS99.2.pdf (accessed February 22, 2007).
39. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-itm version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-26.
40. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-72.
41. Winters SJ, Kelley DE, Goodpasteur B. The analog free testosterone assay: Are the results in men clinically useful? Clin Chem 1998; 44: 2178-82.
42. Guay AT. Screening for androgen deficiency in women: Methodological and interpretive issues. Fertil Steril 2002; 77 (suppl 4): S83-8.
43. Wilke TJ, Utley DJ. Total testosterone, free-androgen index, calculated free testosterone, and the free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin. Clin Chem 1987; 33: 1372-5.
44. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative Insulin Sensitivity Check Index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
45. Jeppesen J, Ole Hein O, Suadicani P, Gyntelberg F. Low triglycerides-high high-density lipoprotein cholesterol and risk of heart disease. Arch Intern Med 2001; 161: 361-6.
46. Jannel WB. The Framingham Study: Its 50-year legacy and future promise. J Atheroscler Thromb 2000; 6: 60-6.
47. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, McKinlay JB. Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts Male Aging Study. Prev Med 2000; 30: 328-38.
48. Sattar N, Gaw A, Scherbakava O, Ford I, St O'Reilley OJ, Haffner SM, Isles C, Macfarlane PM, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-9.
49. El-Sakka A, Morsy AM, Fagih BI, Nassar AH. Coronary artery risk factors in patients with erectile dysfunction. J Urol 2004; 172: 251-4.
50. Ellison RC, Zhang Y, Wagenknecht LE, Eckfeldt JH, Hopkins PN, Pankow JS, Djousse L, Carr JJ. Relation of the metabolic syndrome to calcified atherosclerotic plaque in the coronary arteries and aorta. Am J Cardiol 2005; 95: 1180-6.
51. Ferreira I, Henry RM, Twisk JW, van Mechelen W, Kemper HC, Stehouwer CD, Amsterdam Growth and Health Longitudinal Study. The metabolic syndrome, cardiopulmonary fitness, and subcutaneous trunk fat as independent determinants of arterial stiffness. The Amsterdam growth and Health Longitudinal Study. Arch Intern Med 2005; 165: 875-82.
52. Bocchio M, Desideri G, Scarpelli P, Necozione S, Properzi G, Spartera C, Francavilla F, Ferri C, Francavilla S. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol 2004; 171: 1601-4.
53. Giugliano F, Esposito K, Di Palo C, Ciotola M, Giugliano G, Marfella R, D'Armiento M, Giugliano D. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest 2004; 27: 665-9.
54. Chung WS, Sohn JH, Park YY. Is obesity and underlying factor in erectile dysfunction? Eur Urol 1999; 36: 68-70.
55. Kalme T, Seppala M, Qiao Q, Koistinen R, Nissinen A, Harrela M, Loukovaara M, Leinonen P, Tuomilehto J. Sex hormone binding-globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 2005; 90: 1550-6.
56. Garcia-Puig J, Ruilope LM, Luque M, Fernandez J, Ortega R, Dal-Re R, AVANT Study Group Investigators. Glucose metabolism in patients with essential hypertension. Am J Med 2006; 119: 318-26.
57. Mohteshamzadeh M, Wilkinson R, Thomas SHL. Insulin resistance in men with treated hypertension at increased risk for cardiovascular disease: Results of a 3-year study. Am J Hypertens 2005; 18: 452-6.
58. O'Meara JG, Kardia SL, Armon JJ, Brown CA, Boerwinkle E, Turner ST. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA Study. Arch Intern Med 2004; 164: 1313-8.
59. Nigro J, Osman N, Dart AM, Little PJ. Insulin resistance and atherosclerosis. Endocr Rev 2006; 27: 242-59.
60. Al Suwaidi J, Higano ST, Holmes DR Jr, Lennon R, Lerman A. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 2001; 37: 1523-8.
61. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2595-600.
62. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol 2005; 63: 239-50.
63. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003; 24: 313-40.
64. Wu FCW, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24: 183-217.
65. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-76.
66. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99: 1666-70.
67. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol 2003; 58: 632-8.
68. Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: From the male attitudes regarding sexual health survey. J Sex Med 2007; 4: 57-65.
69. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol 2005; 63: 280-93.
70. Zhang XH, Filippi S, Morelli A, Vignozzi L, Luconi M, Donate S, Forti G, Maggi M. Testosterone restored diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 2006; 3: 253-64.
71. Yaman O, Akand M, Gursoy A, Erdogan MF, Anafarta K. The effect of diabetes mellitus treatment and good glycemic control on the erectile function in men with diabetes mellitus-induced erectile dysfunction: A pilot study. J Sex Med 2006; 3: 344-8.